JURA Bio, Inc. is involved in generative machine learning applied to laboratory settings, specifically in protein and biologic sequence design. The company has developed a manufacturing-aware generative model architecture to reduce the cost of designing new proteins significantly.

JURA Bio, Inc.

Google Health is a division of Google that focuses on the research and development of technologies to improve health and wellness. It leverages Google's expertise in data analytics, machine learning, and artificial intelligence to address various health-related challenges.

Google Health

JURA Bio, Inc. | 1,941 followers on LinkedIn. Building the future of cell-based therapies. | CAR-T is for more than just oncology. Using the full potential of gene editing, we are creating a therapeutic platform for cell based therapies that are not just disease modifying: they are curative and definitive.

Member Board of Directors @ JURA Bio, Inc. | Biotech Strategy Leader

Michelle Berg

Senior VP of R&D | Immunotherapy, Biologics Discovery

Cameron Gardner

Director of Machine Learning at JURA Bio. Probabilistic machine learning | immunology | molecular biology

Mattia Gollub

Postdoc with David Blei // ML at JURA Bio

Eli Weinstein

Tomorrow, Election Day, Eli Weinstein will present our work on *physically sampling* generative models of proteins by the quadrillion. #MoML2024 in Cambridge, MA: today is the last day to register! JURA Bio, Inc.

Elizabeth Wood

So pleased our work on #VariationalSynthesis was selected as one of the top 4 papers at MIT Jameel Clinic - AI & Health 's 5th Molecular Machine Learning Conference, #MoML2024 . Eli Weinstein will be giving a short talk in person if you'd like to learn more live. Early bird registration is already sold out, but you can get regular tickets or onto the waitlist at https://moml.mit.edu . And you can always reach out to us if you have to miss the in-person event but would still like to learn more about manufacturing-aware generative protein models. JURA Bio, Inc.

You can register now for free at https://lnkd.in/eeY6BkDC to listen to JURA Bio CEO Elizabeth Wood speak to the possibilities of foundation models in biology. She puts #variationalsynthesis as a tool for building incomparably large data sets for training these models into context.

CAIRE represents an incredible effort by JURA's head of machine learning research Eli Weinstein and David Blei (Columbia), as well as Elizabeth Wood to bring insights into clinical efficacy as far upstream as possible into the therapeutic design process. Pleased to release it to today and we encourage you to check out the blog post: https://lnkd.in/e7A3tyWr

Loved this closer look that Will Connell took into #VariationalSynthesis . I encourage you to give a read -- and in general, check out his substack, which I've enjoyed catchup up on: Behind BioML https://lnkd.in/ecTKavuf JURA Bio, Inc.

For those of you who enjoy learning through audio, please check out the new Deep Dive podcast into Variational Synthesis made in collaboration with Google's NotebookLM.

🧬 Direct synthesis of trillions of AI-designed protein candidates! It's a great feeling to share our results designing and building peta-scale libraries of antibodies, antigens and polymerases. High five to everyone involved at JURA Bio, Inc. , and in particular Eli Weinstein , Andrei Slabodkin and our CEO Elizabeth Wood , such a wonderful team to work with!

We invite you to read about our newest technology release at https://lnkd.in/eM7GbgWV . We've brought the cost of taking machine learning designed proteins off the computer into the real-world by a trillion-fold. #VariationalSynthesis #BioAI

We're excited to join the conversation at LSX World Congress USA tomorrow in Boston! Catch our CEO, Elizabeth Wood , on Day 1 from 1:40 to 2:30 PM EDT as she shares insights on "What trends in oncology and partnering are shaping the future of cancer treatment and where are the opportunities for innovation" with Alex Philippidis , Senior Business editor at Genetic Engineering & Biotechnology News , as moderator. This session will dive deep into the key areas that AI been reshaping — or has begun to reshape — cancer drug development. 🗓️ Explore more and check out the full agenda at www.lsxleaders.com/USA . #LSXUSA #Healthtech #Biotechnology #AI #MachineLearning #Oncology

Excited to be traveling out to Scotts Valley, California next week to speak at the Nucleate #AlumniSummit . I've always been such a big fan of this student-led organization: its community, and the environment for success that everyone at Nucleate has been building is really special; and it's a privilege to get to continue to support it as I can. Also excited to share a little of what JURA Bio, Inc. has been up to. With a couple of big preprints coming out in a few weeks -- one on our manufacturing aware AI-model architectures allowing us to build quadrillion-dollar protein libraries in the real world -- and another on our causal methods for mining observational experiments for indications of clinical safety and efficacy -- I hope it's an opportunity to give a glimpse of the future that AI-led-bio can achieve. If you're planning to be there, please give a 👋 https://lnkd.in/eSPkZepk

Metric
Company Name	JURA Bio, Inc.	Google Health
Symbol
MSH ID	BIO:JURA	GOOGLE:HEALTH
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Healthcare Technology
Country	US
Stage
Employee Count
Website	jura.bio	health.google
LinkedIn	jurabio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

JURA

BIO:JURA

JURA Bio, Inc.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue